Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model
Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The therapeutic protocols adopted for dogs and humans are very similar, involving surgical options such as amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. However, hematologic, gas...
Gespeichert in:
Veröffentlicht in: | Veterinary & comparative oncology 2018-12, Vol.16 (4), p.478-488 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 488 |
---|---|
container_issue | 4 |
container_start_page | 478 |
container_title | Veterinary & comparative oncology |
container_volume | 16 |
creator | Rici, R. E. G. Will, S. E. A. L. Luna, A. C. L. Melo, L. F. Santos, A. C. Rodrigues, R. F. Leandro, R. M. Maria, D. A. |
description | Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The therapeutic protocols adopted for dogs and humans are very similar, involving surgical options such as amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. However, hematologic, gastrointestinal and renal toxicity may occur because of chemotherapy treatments. Recent study clearly showed that mesenchymal stem cells (MSCs) combined with recombinant human bone morphogenetic protein (rhBMP‐2) may be associated with decreases of the tumorigenic potential of canine OSA. The aim of this study was to analyse the efficacy of chemotherapy with carboplatin and rhBMP‐2 with MSCs in a canine OSA in vivo model. Canine OSA cells were implanted in mice Balb‐c/nude with MSCs, rhBMP‐2 and carboplatin. Flow cytometry and PCR for markers involved in tumour suppression pathways were analysed. Results showed that the combination of MSCs and rhBMP‐2 reduced tumour mass and infiltration of neoplastic cells in tissues more efficiently than carboplatin alone. Thus it was demonstrated that the use of rhBMP‐2 and MSCs, in combination with conventional antineoplastic, may be an efficient treatment strategy. |
doi_str_mv | 10.1111/vco.12404 |
format | Article |
fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_vco_12404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>VCO12404</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3254-1f7f3ac16dfc714af38bbd0e87f0c8fe86861c282c3b8581d06fa92d975c6a8d3</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EoqWw4AeQt0iktZ2Xs0QRL6lSN8A2cvygRokd2aFVPoJ_xm3a7vBiPJo5c0dzAbjFaI7DW2y4nWOSoOQMTHGSZ1FKSXF-yjGagCvvvxEiJInJJZiQIqeYpOkU_Ja2rbVhvbYG9mvpWDdAqyBnRhsJre-l9cxx2zK41f362KhtCC1zzm5hYFrIZdP4h0Pdum5tv6SRveawc7aX2kBmRJh2te2asM7AfWkXN3pjw4yQzTW4UKzx8ubwz8DH89N7-RotVy9v5eMy4jFJkwirXMWM40wonuOEqZjWtUCS5gpxqiTNaIY5oYTHNQ33C5QpVhBR5CnPGBXxDNyPutxZ751UVed0uGaoMKp2llbB0mpvaWDvRrb7qVspTuTRwwAsRmCrGzn8r1R9lqtR8g8VEYPp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Rici, R. E. G. ; Will, S. E. A. L. ; Luna, A. C. L. ; Melo, L. F. ; Santos, A. C. ; Rodrigues, R. F. ; Leandro, R. M. ; Maria, D. A.</creator><creatorcontrib>Rici, R. E. G. ; Will, S. E. A. L. ; Luna, A. C. L. ; Melo, L. F. ; Santos, A. C. ; Rodrigues, R. F. ; Leandro, R. M. ; Maria, D. A.</creatorcontrib><description>Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The therapeutic protocols adopted for dogs and humans are very similar, involving surgical options such as amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. However, hematologic, gastrointestinal and renal toxicity may occur because of chemotherapy treatments. Recent study clearly showed that mesenchymal stem cells (MSCs) combined with recombinant human bone morphogenetic protein (rhBMP‐2) may be associated with decreases of the tumorigenic potential of canine OSA. The aim of this study was to analyse the efficacy of chemotherapy with carboplatin and rhBMP‐2 with MSCs in a canine OSA in vivo model. Canine OSA cells were implanted in mice Balb‐c/nude with MSCs, rhBMP‐2 and carboplatin. Flow cytometry and PCR for markers involved in tumour suppression pathways were analysed. Results showed that the combination of MSCs and rhBMP‐2 reduced tumour mass and infiltration of neoplastic cells in tissues more efficiently than carboplatin alone. Thus it was demonstrated that the use of rhBMP‐2 and MSCs, in combination with conventional antineoplastic, may be an efficient treatment strategy.</description><identifier>ISSN: 1476-5810</identifier><identifier>EISSN: 1476-5829</identifier><identifier>DOI: 10.1111/vco.12404</identifier><identifier>PMID: 29781255</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>animal models ; Animals ; antineoplastic ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - therapeutic use ; Bone Marrow Transplantation - methods ; Bone Marrow Transplantation - veterinary ; Bone Morphogenetic Protein 2 - administration & dosage ; Bone Morphogenetic Protein 2 - therapeutic use ; Bone Neoplasms - therapy ; Bone Neoplasms - veterinary ; Carboplatin - administration & dosage ; Carboplatin - therapeutic use ; Combined Modality Therapy - veterinary ; Disease Models, Animal ; Dog Diseases - therapy ; Dogs ; Female ; Flow Cytometry - veterinary ; Male ; Mice, Inbred BALB C ; Mice, Nude ; MSCs ; Neoplasms, Experimental - therapy ; Osteosarcoma - therapy ; Osteosarcoma - veterinary ; Real-Time Polymerase Chain Reaction ; Recombinant Proteins ; rhBMP‐2 therapy ; Stem Cell Transplantation - methods ; Stem Cell Transplantation - veterinary ; tumour</subject><ispartof>Veterinary & comparative oncology, 2018-12, Vol.16 (4), p.478-488</ispartof><rights>2018 John Wiley & Sons Ltd</rights><rights>2018 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3254-1f7f3ac16dfc714af38bbd0e87f0c8fe86861c282c3b8581d06fa92d975c6a8d3</citedby><cites>FETCH-LOGICAL-c3254-1f7f3ac16dfc714af38bbd0e87f0c8fe86861c282c3b8581d06fa92d975c6a8d3</cites><orcidid>0000-0001-6573-5612</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fvco.12404$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fvco.12404$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29781255$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rici, R. E. G.</creatorcontrib><creatorcontrib>Will, S. E. A. L.</creatorcontrib><creatorcontrib>Luna, A. C. L.</creatorcontrib><creatorcontrib>Melo, L. F.</creatorcontrib><creatorcontrib>Santos, A. C.</creatorcontrib><creatorcontrib>Rodrigues, R. F.</creatorcontrib><creatorcontrib>Leandro, R. M.</creatorcontrib><creatorcontrib>Maria, D. A.</creatorcontrib><title>Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model</title><title>Veterinary & comparative oncology</title><addtitle>Vet Comp Oncol</addtitle><description>Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The therapeutic protocols adopted for dogs and humans are very similar, involving surgical options such as amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. However, hematologic, gastrointestinal and renal toxicity may occur because of chemotherapy treatments. Recent study clearly showed that mesenchymal stem cells (MSCs) combined with recombinant human bone morphogenetic protein (rhBMP‐2) may be associated with decreases of the tumorigenic potential of canine OSA. The aim of this study was to analyse the efficacy of chemotherapy with carboplatin and rhBMP‐2 with MSCs in a canine OSA in vivo model. Canine OSA cells were implanted in mice Balb‐c/nude with MSCs, rhBMP‐2 and carboplatin. Flow cytometry and PCR for markers involved in tumour suppression pathways were analysed. Results showed that the combination of MSCs and rhBMP‐2 reduced tumour mass and infiltration of neoplastic cells in tissues more efficiently than carboplatin alone. Thus it was demonstrated that the use of rhBMP‐2 and MSCs, in combination with conventional antineoplastic, may be an efficient treatment strategy.</description><subject>animal models</subject><subject>Animals</subject><subject>antineoplastic</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Bone Marrow Transplantation - methods</subject><subject>Bone Marrow Transplantation - veterinary</subject><subject>Bone Morphogenetic Protein 2 - administration & dosage</subject><subject>Bone Morphogenetic Protein 2 - therapeutic use</subject><subject>Bone Neoplasms - therapy</subject><subject>Bone Neoplasms - veterinary</subject><subject>Carboplatin - administration & dosage</subject><subject>Carboplatin - therapeutic use</subject><subject>Combined Modality Therapy - veterinary</subject><subject>Disease Models, Animal</subject><subject>Dog Diseases - therapy</subject><subject>Dogs</subject><subject>Female</subject><subject>Flow Cytometry - veterinary</subject><subject>Male</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Nude</subject><subject>MSCs</subject><subject>Neoplasms, Experimental - therapy</subject><subject>Osteosarcoma - therapy</subject><subject>Osteosarcoma - veterinary</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>Recombinant Proteins</subject><subject>rhBMP‐2 therapy</subject><subject>Stem Cell Transplantation - methods</subject><subject>Stem Cell Transplantation - veterinary</subject><subject>tumour</subject><issn>1476-5810</issn><issn>1476-5829</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EoqWw4AeQt0iktZ2Xs0QRL6lSN8A2cvygRokd2aFVPoJ_xm3a7vBiPJo5c0dzAbjFaI7DW2y4nWOSoOQMTHGSZ1FKSXF-yjGagCvvvxEiJInJJZiQIqeYpOkU_Ja2rbVhvbYG9mvpWDdAqyBnRhsJre-l9cxx2zK41f362KhtCC1zzm5hYFrIZdP4h0Pdum5tv6SRveawc7aX2kBmRJh2te2asM7AfWkXN3pjw4yQzTW4UKzx8ubwz8DH89N7-RotVy9v5eMy4jFJkwirXMWM40wonuOEqZjWtUCS5gpxqiTNaIY5oYTHNQ33C5QpVhBR5CnPGBXxDNyPutxZ751UVed0uGaoMKp2llbB0mpvaWDvRrb7qVspTuTRwwAsRmCrGzn8r1R9lqtR8g8VEYPp</recordid><startdate>201812</startdate><enddate>201812</enddate><creator>Rici, R. E. G.</creator><creator>Will, S. E. A. L.</creator><creator>Luna, A. C. L.</creator><creator>Melo, L. F.</creator><creator>Santos, A. C.</creator><creator>Rodrigues, R. F.</creator><creator>Leandro, R. M.</creator><creator>Maria, D. A.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-6573-5612</orcidid></search><sort><creationdate>201812</creationdate><title>Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model</title><author>Rici, R. E. G. ; Will, S. E. A. L. ; Luna, A. C. L. ; Melo, L. F. ; Santos, A. C. ; Rodrigues, R. F. ; Leandro, R. M. ; Maria, D. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3254-1f7f3ac16dfc714af38bbd0e87f0c8fe86861c282c3b8581d06fa92d975c6a8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>animal models</topic><topic>Animals</topic><topic>antineoplastic</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Bone Marrow Transplantation - methods</topic><topic>Bone Marrow Transplantation - veterinary</topic><topic>Bone Morphogenetic Protein 2 - administration & dosage</topic><topic>Bone Morphogenetic Protein 2 - therapeutic use</topic><topic>Bone Neoplasms - therapy</topic><topic>Bone Neoplasms - veterinary</topic><topic>Carboplatin - administration & dosage</topic><topic>Carboplatin - therapeutic use</topic><topic>Combined Modality Therapy - veterinary</topic><topic>Disease Models, Animal</topic><topic>Dog Diseases - therapy</topic><topic>Dogs</topic><topic>Female</topic><topic>Flow Cytometry - veterinary</topic><topic>Male</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Nude</topic><topic>MSCs</topic><topic>Neoplasms, Experimental - therapy</topic><topic>Osteosarcoma - therapy</topic><topic>Osteosarcoma - veterinary</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>Recombinant Proteins</topic><topic>rhBMP‐2 therapy</topic><topic>Stem Cell Transplantation - methods</topic><topic>Stem Cell Transplantation - veterinary</topic><topic>tumour</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rici, R. E. G.</creatorcontrib><creatorcontrib>Will, S. E. A. L.</creatorcontrib><creatorcontrib>Luna, A. C. L.</creatorcontrib><creatorcontrib>Melo, L. F.</creatorcontrib><creatorcontrib>Santos, A. C.</creatorcontrib><creatorcontrib>Rodrigues, R. F.</creatorcontrib><creatorcontrib>Leandro, R. M.</creatorcontrib><creatorcontrib>Maria, D. A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Veterinary & comparative oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rici, R. E. G.</au><au>Will, S. E. A. L.</au><au>Luna, A. C. L.</au><au>Melo, L. F.</au><au>Santos, A. C.</au><au>Rodrigues, R. F.</au><au>Leandro, R. M.</au><au>Maria, D. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model</atitle><jtitle>Veterinary & comparative oncology</jtitle><addtitle>Vet Comp Oncol</addtitle><date>2018-12</date><risdate>2018</risdate><volume>16</volume><issue>4</issue><spage>478</spage><epage>488</epage><pages>478-488</pages><issn>1476-5810</issn><eissn>1476-5829</eissn><abstract>Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The therapeutic protocols adopted for dogs and humans are very similar, involving surgical options such as amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. However, hematologic, gastrointestinal and renal toxicity may occur because of chemotherapy treatments. Recent study clearly showed that mesenchymal stem cells (MSCs) combined with recombinant human bone morphogenetic protein (rhBMP‐2) may be associated with decreases of the tumorigenic potential of canine OSA. The aim of this study was to analyse the efficacy of chemotherapy with carboplatin and rhBMP‐2 with MSCs in a canine OSA in vivo model. Canine OSA cells were implanted in mice Balb‐c/nude with MSCs, rhBMP‐2 and carboplatin. Flow cytometry and PCR for markers involved in tumour suppression pathways were analysed. Results showed that the combination of MSCs and rhBMP‐2 reduced tumour mass and infiltration of neoplastic cells in tissues more efficiently than carboplatin alone. Thus it was demonstrated that the use of rhBMP‐2 and MSCs, in combination with conventional antineoplastic, may be an efficient treatment strategy.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>29781255</pmid><doi>10.1111/vco.12404</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-6573-5612</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1476-5810 |
ispartof | Veterinary & comparative oncology, 2018-12, Vol.16 (4), p.478-488 |
issn | 1476-5810 1476-5829 |
language | eng |
recordid | cdi_crossref_primary_10_1111_vco_12404 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | animal models Animals antineoplastic Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Bone Marrow Transplantation - methods Bone Marrow Transplantation - veterinary Bone Morphogenetic Protein 2 - administration & dosage Bone Morphogenetic Protein 2 - therapeutic use Bone Neoplasms - therapy Bone Neoplasms - veterinary Carboplatin - administration & dosage Carboplatin - therapeutic use Combined Modality Therapy - veterinary Disease Models, Animal Dog Diseases - therapy Dogs Female Flow Cytometry - veterinary Male Mice, Inbred BALB C Mice, Nude MSCs Neoplasms, Experimental - therapy Osteosarcoma - therapy Osteosarcoma - veterinary Real-Time Polymerase Chain Reaction Recombinant Proteins rhBMP‐2 therapy Stem Cell Transplantation - methods Stem Cell Transplantation - veterinary tumour |
title | Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T02%3A23%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20therapy%20of%20canine%20osteosarcoma%20with%20canine%20bone%20marrow%20stem%20cells,%20bone%20morphogenetic%20protein%20and%20carboplatin%20in%20an%20in%20vivo%20model&rft.jtitle=Veterinary%20&%20comparative%20oncology&rft.au=Rici,%20R.%20E.%20G.&rft.date=2018-12&rft.volume=16&rft.issue=4&rft.spage=478&rft.epage=488&rft.pages=478-488&rft.issn=1476-5810&rft.eissn=1476-5829&rft_id=info:doi/10.1111/vco.12404&rft_dat=%3Cwiley_cross%3EVCO12404%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/29781255&rfr_iscdi=true |